VRCA — Verrica Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$5.36
+$0.12 (+2.29%)
Verrica Pharmaceuticals Inc (VRCA) is a biotechnology company listed on NASDAQ. It is led by Jayson M. Rieger M.B.A., Ph.D., based in 44 West Gay Street, West Chester, PA, United States, 19380, with about 71 employees. Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company's product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma; and VP-103, a cantharidin-based product candidate for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Latest reported VRCA revenue for 2025-09-30 was $14.3M. Net income was -$274.0K. Revenue was up 12.9% from 2025-06-30 to 2025-09-30. VRCA currently screens at market cap $79.7M.
Use this VRCA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VRCA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VRCA SEC filings page. Lician reads the product cache first so this HTML stays unique to Verrica Pharmaceuticals Inc even when a live quote feed is slow.
About Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company's product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma; and VP-103, a cantharidin-based product candidate for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
VRCA Key Statistics
Market Cap
$79.72M
Volume
532,656
Previous Close
$4.91
Day Range
$4.90 – $5.65
EPS
-$1.48
Revenue
$7.57M
Net Income
-$76.58M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+47.7%
Profit Margin
-1012.1%
Employees
71
VRCA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $7.57M | $5.12M | $9.03M | $12.00M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$76.58M | -$67.00M | -$24.49M | -$35.08M |
| EPS (Diluted) | -$1.48 | -$1.48 | -$0.72 | -$1.30 |
Total Assets
$54.13M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$46.33M
Operating Cash Flow
-$60.93M
Free Cash Flow
$0.00
Verrica Pharmaceuticals Inc Company Information
- President, CEO & Director
- Jayson M. Rieger M.B.A., Ph.D.
- Headquarters
- 44 West Gay Street, West Chester, PA, United States, 19380
- Website
- www.verrica.com
- Phone
- 484 453 3300
- IPO / Founded
- 2018-06-15
- Sector
- Healthcare
- Industry
- Biotechnology